

The February 10, 2016, article by Hortobagyi et al entitled “Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2” (J Clin Oncol 34:419-426, 2016) was published online October 26, 2015, with errors in the AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST section.

Dr. Baselga’s COIs were given as:

José Baselga

Honoraria: Novartis, Infinity

Consulting or Advisory Role: Novartis, Verastem, Infinity

They should have read as:

José Baselga

Leadership: Infinity Pharmaceuticals and Aura Biosciences
Stock or Other Ownership: PMV Pharma, Juno Therapeutics, Infinity Pharmaceuticals, GRAIL, Aura Biomedical, Apogen, Seragon, Aragon, Verastem

Honoraria: Infinity **Pharmaceuticals, PMV Pharma, Juno Therapeutics, GRAIL, Seragon**

Consulting or Advisory Role: Novartis, **Eli Lilly, GRAIL, AstraZeneca**

Research Funding: Roche/Genentech

Travel, Accommodations, Expenses: Roche/Genentech

This has been corrected as of January 11, 2019. The author apologizes for the errors.